HSPG2 and in situ carcinoma: The basal membrane perlecan and its binding ligands, including VEGF, SHH, KGF, Flt-1, and Flk-1, were found to be differentially expressed in oral epithelial dysplasia and carcinoma in situ indicating to the important contribution of perlecan in the regulation of these factors signaling (57).